Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer (Q33558951)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

pancreatic cancer

1 reference

based on heuristic

inferred from title

Jean-Nicolas Vauthey

12

object named as

Jean-Nicolas Vauthey

0 references

6

object named as

Huamin Wang

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

13

object named as

Jason B Fleming

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Ching-Wei D Tzeng

1

object named as

Ching-Wei D Tzeng

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

5

object named as

Sunil Krishnan

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Christopher H Crane

7

object named as

Christopher H Crane

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Gauri R Varadhachary

9

object named as

Gauri R Varadhachary

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

11

object named as

Thomas A Aloia

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

author name string

Aparna Balachandran

2

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Mediha Ahmad

3

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Jeffrey E Lee

4

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Robert A Wolff

8

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Peter W T Pisters

10

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Matthew H G Katz

14

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

29 August 2013

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Hepato Pancreato Biliary

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

430-438

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008161

14 July 2018

The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008161

14 July 2018

Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008161

14 July 2018

Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008161

14 July 2018

Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008161

14 July 2018

The prognostic and predictive value of serum CA19.9 in pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008161

14 July 2018

Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008161

14 July 2018

Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008161

14 July 2018

Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008161

14 July 2018

Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008161

14 July 2018

Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008161

14 July 2018

Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008161

14 July 2018

Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008161

14 July 2018

Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008161

14 July 2018

Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008161

31 October 2018

Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008161

31 October 2018

Selective use of staging laparoscopy based on carbohydrate antigen 19-9 level and tumor size in patients with radiographically defined potentially or borderline resectable pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008161

31 October 2018

Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008161

31 October 2018

Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008161

31 October 2018

Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008161

31 October 2018

The Use of Adjusted Preoperative CA 19-9 to Predict the Recurrence of Resectable Pancreatic Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008161

31 October 2018

Preoperative CA 19-9 and the Yield of Staging Laparoscopy in Patients with Radiographically Resectable Pancreatic Adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008161

10 December 2018

CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23991810

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Utility of serum CA 19-9 monitoring in preoperative radiotherapy for pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23991810

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23991810

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/23991810

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level

1 reference

https://pubmed.ncbi.nlm.nih.gov/23991810

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical significance of CEA and CA19-9 in postoperative follow-up of colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23991810

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Carcinoembryonic antigen as a predictor of pathologic response and a prognostic factor in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and surgery

1 reference

https://pubmed.ncbi.nlm.nih.gov/23991810

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators

1 reference

https://pubmed.ncbi.nlm.nih.gov/23991810

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Borderline resectable pancreatic cancer: what have we learned and where do we go from here?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23991810

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/HPB.12154

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33558951&oldid=1947027024"